These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 11129170)

  • 1. ZD1839 ('Iressa') as an anticancer agent.
    Baselga J; Averbuch SD
    Drugs; 2000; 60 Suppl 1():33-40; discussion 41-2. PubMed ID: 11129170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
    Di Gennaro E; Barbarino M; Bruzzese F; De Lorenzo S; Caraglia M; Abbruzzese A; Avallone A; Comella P; Caponigro F; Pepe S; Budillon A
    J Cell Physiol; 2003 Apr; 195(1):139-50. PubMed ID: 12599217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZD1839: targeting the epidermal growth factor receptor in cancer therapy.
    Herbst RS
    Expert Opin Investig Drugs; 2002 Jun; 11(6):837-49. PubMed ID: 12036427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I studies of ZD1839 in patients with common solid tumors.
    Lorusso PM
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):21-9. PubMed ID: 12644981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib, a novel, orally administered agent for the treatment of cancer.
    Ranson M; Wardell S
    J Clin Pharm Ther; 2004 Apr; 29(2):95-103. PubMed ID: 15068398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
    Baselga J; Rischin D; Ranson M; Calvert H; Raymond E; Kieback DG; Kaye SB; Gianni L; Harris A; Bjork T; Averbuch SD; Feyereislova A; Swaisland H; Rojo F; Albanell J
    J Clin Oncol; 2002 Nov; 20(21):4292-302. PubMed ID: 12409327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
    Von Pawel J
    Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
    Herbst RS
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ZD1839 (Iressa) in non-small-cell lung cancer.
    Herbst RS; Khuri FR; Fossella FV; Glisson BS; Kies MS; Pisters KM; Riddle JR; Terry KA; Lee JS
    Clin Lung Cancer; 2001 Aug; 3(1):27-32. PubMed ID: 14656386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-EGF receptor therapy.
    Blackledge G; Averbuch S; Kay A; Barton J
    Prostate Cancer Prostatic Dis; 2000 Dec; 3(4):296-302. PubMed ID: 12497082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil.
    Magné N; Fischel JL; Tiffon C; Formento P; Dubreuil A; Renée N; Formento JL; Francoual M; Ciccolini J; Etienne MC; Milano G
    Br J Cancer; 2003 Aug; 89(3):585-92. PubMed ID: 12888834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.
    Raben D; Helfrich BA; Chan D; Johnson G; Bunn PA
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):37-46. PubMed ID: 11894012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.
    Sgambato A; Camerini A; Faraglia B; Ardito R; Bianchino G; Spada D; Boninsegna A; Valentini V; Cittadini A
    J Cell Physiol; 2004 Oct; 201(1):97-105. PubMed ID: 15281092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).
    Heimberger AB; Learn CA; Archer GE; McLendon RE; Chewning TA; Tuck FL; Pracyk JB; Friedman AH; Friedman HS; Bigner DD; Sampson JH
    Clin Cancer Res; 2002 Nov; 8(11):3496-502. PubMed ID: 12429640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
    Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
    Wakeling AE; Guy SP; Woodburn JR; Ashton SE; Curry BJ; Barker AJ; Gibson KH
    Cancer Res; 2002 Oct; 62(20):5749-54. PubMed ID: 12384534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies with ZD1839 in preclinical models.
    Sirotnak FM
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):12-20. PubMed ID: 12644980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ZD1839 (Iressa): for more than just non-small cell lung cancer.
    Ranson M
    Oncologist; 2002; 7 Suppl 4():16-24. PubMed ID: 12202784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.
    Albanell J; Rojo F; Baselga J
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):56-66. PubMed ID: 11706397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.